Financial Contrast: Oculis (NASDAQ:OCS) versus Silo Pharma (NASDAQ:SILO)

Silo Pharma (NASDAQ:SILO) and Oculis (NASDAQ:OCS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Profitability

This table compares Silo Pharma and Oculis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silo Pharma	-6,726.39%	-81.75%	-66.35%
Oculis	-6,777.18%	-42.61%	-35.23%

Volatility & Risk

Silo Pharma has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Oculis has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.

Insider & Institutional Ownership

5.6% of Silo Pharma shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Silo Pharma and Oculis, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silo Pharma	1	0	0	0	1.00
Oculis	1	0	9	0	2.80

Oculis has a consensus price target of $39.44, suggesting a potential upside of 295.23%. Given Oculis’ stronger consensus rating and higher possible upside, analysts clearly believe Oculis is more favorable than Silo Pharma.

Valuation & Earnings

This table compares Silo Pharma and Oculis”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silo Pharma	$70,000.00	39.07	-$4.23 million	($4.36)	-0.39
Oculis	$1.45 million	399.06	-$119.44 million	($1.74)	-5.74

Silo Pharma has higher earnings, but lower revenue than Oculis. Oculis is trading at a lower price-to-earnings ratio than Silo Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Oculis beats Silo Pharma on 9 of the 14 factors compared between the two stocks.

About Silo Pharma

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.